



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/718,513	11/24/2003	Masao Tasaka	245787US0	1957

22850 7590 11/18/2004

OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.  
1940 DUKE STREET  
ALEXANDRIA, VA 22314

EXAMINER

SAMSON, MARIA TERESA D

ART UNIT PAPER NUMBER

1638

DATE MAILED: 11/18/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b> 10/718,513	<b>Applicant(s)</b> TASAKA ET AL.	
	<b>Examiner</b> Maria Teresa Samson	<b>Art Unit</b> 1638	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-10 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-10 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |  |
|---|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)            |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date ____ | 6) <input type="checkbox"/> Other: ____  |

***Election/Restrictions***

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claim 1, drawn to an *Arabidopsis thaliana* ss12 slr mutant with lateral roots, classified in class 435, subclass 441.
- II. Claim 2, drawn to an *Arabidopsis thaliana* ss12 slr mutant with no lateral roots, classified in class 435, subclass 441.
- III. Claim 3, drawn to an *Arabidopsis thaliana* ss12 slr mutant with recovered lateral root formation, classified in class 435, subclass 441.
- IV. Claims 4-7 and 10, drawn to a nucleic acids, classified in class 536, subclass 23.6.
- V. Claims 8 and 9, drawn to a protein of SEQ ID NO: 2, classified in class 530, subclass 350.

2. The inventions are distinct from each other because:

(A.) Groups I, II and III are independent and distinct. Groups I, II and III are drawn to mutant *Arabidopsis thaliana* plants with different phenotypes. The mutant *Arabidopsis thaliana* plants of Group I have lateral roots. The mutant *Arabidopsis thaliana* plants of Group II have no lateral roots whereas the mutant *Arabidopsis thaliana* plants of Group III have recovered lateral root formation. Since their phenotypes are different from each other, the searches are not coextensive. A search on Group I or Group II could not necessarily find prior art on Group III.

(B.) Groups I, II, and III are unrelated to Group IV. The mutant plants of Groups I, II, and III are unrelated to the nucleic acid of Group IV because their compositions are

Art Unit: 1638

different. The mutant plants of Groups I, II and III are composed of the nucleic acid of Group IV as well as proteins and other chemicals. They work together to make the mutant plants of Groups I, II, and III. Group IV is made up of nucleotides only. Thus, the searches are not coextensive. A search on Group I or Group II or Group III could not necessarily find prior art on the nucleic acid of Group IV and vice versa.

(C.) Groups I, II, and III are unrelated to Group V. The mutant plants of Groups I, II, and III are unrelated to Groups V because their compositions are different. The mutant plants of Groups I, II and III are composed of the protein of Group V as well as other proteins, chemicals and nucleic acids. They work together to make the mutant plants of Groups I, II, and III. The protein of Group V is made up of amino acids only. Thus, the searches are not coextensive. A search on Group I or Group II or Group III would not necessarily find prior art on the protein of Group V and vice versa.

(D.) Group IV is independent and distinct from Group V. The DNA molecule of Group IV and the protein of Group V are distinct because they are physically and functionally distinct chemical entities. The DNA molecule of Group IV is made up of nucleotides while the protein of Group V is composed of amino acids. Furthermore, the DNA molecule may be used for processes other than the production of the protein such as in nucleic hybridization assays and the protein can be made by another materially different process such as purification from the natural source. The search requirement for protein involves both text and amino acid sequence searches while the search for DNA requires only a DNA sequence search. Therefore, the searches are not coextensive.

Nucleotide sequences encoding different proteins are structurally distinct chemical compounds that are unrelated to one another. These sequences are thus deemed to

Art Unit: 1638

normally constitute **independent and distinct** inventions within the meaning of 35 U.S.C. 121. Each sequence requires an independent search of the sequence databases. Absent evidence to the contrary, each such nucleotide is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq (see MPEP 803.04 and 2434).

Upon election of a Group, Applicant is additionally required to select a single nucleotide sequence for said Group, as appropriate. This requirement is not to be construed as a requirement for an election of species, since each nucleotide is not a member of single genus of invention, but constitutes an independent and patentably distinct invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, subject matter and search requirement, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maria Teresa Samson whose telephone number is 571-

Art Unit: 1638

272-3110. The examiner can normally be reached on 7:00-5:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached on 571-272-0804. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance.

Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides

Art Unit: 1638

Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Maria Teresa Samson, Ph.D  
November 10, 2004



ANNE KUBELIK  
PATENT EXAMINER